C4 Therapeutics, Inc.

Historical 13F Holders

Symbol
CCCC
CUSIP
12529R107
All holders as of
Q3 2026
Type
Equity
Class
COM STK
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 12529R107 since 12/18/2024, largest first.

Filer % of Class Filed
Lynx1 Capital Management LP 13G/A
10.0% 8/14/2026
Event 6/30/2026
Soleus Capital Master Fund, L.P. 13G/A
10.0% 2/12/2026
Event 12/31/2025
Sirenia Capital Management LP 13G
9.9% 5/15/2026
Event 3/31/2026
RA Capital Management, L.P. 13G/A
9.9% 11/16/2026
Event 9/30/2026
Squadron Capital Management LLC 13G/A
7.9% 11/16/2026
Event 9/30/2026
BlackRock, Inc. 13G 6.9% 7/27/2026
Event 6/30/2026
Bain Capital Life Sciences Fund II, L.P. 13G
6.3% 10/24/2025
Event 10/17/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
Morgan Stanley 13G/A
8.0%
Checked 5% or less
8/12/2026
Event 6/30/2026
Wasatch Advisors LP 13G/A 4.7% 4/22/2026
Event 3/31/2026
OrbiMed Advisors LLC 13G/A
1.0% 2/17/2026
Event 12/31/2025
Point72 Asset Management, L.P. 13G/A
0.2% 5/15/2026
Event 3/31/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 152 138 M $457M
2026 Q2 148 118 M $548M
2026 Q1 123 84.5 M $221M
2025 Q4 101 79.8 M $153M
2025 Q3 99 52.5 M $117M
2025 Q2 103 54.7 M $78.2M
2025 Q1 116 64.1 M $103M
2024 Q4 117 64.4 M $232M
2024 Q3 122 64.2 M $366M
2024 Q2 116 60.9 M $281M
2024 Q1 107 58.2 M $476M
2023 Q4 93 47.0 M $266M
2023 Q3 85 34.7 M $64.5M
2023 Q2 101 34.2 M $94.1M
2023 Q1 122 37.4 M $117M
2022 Q4 118 39.2 M $231M
2022 Q3 116 39.4 M $346M
2022 Q2 119 39.4 M $298M
2022 Q1 127 37.3 M $905M
2021 Q4 123 35.9 M $1.15B
2021 Q3 115 34.5 M $1.54B
2021 Q2 110 31.9 M $1.21B
2021 Q1 85 25.1 M $927M
2020 Q4 76 22.7 M $744M